Barry D Nelkin

Professor Emeritus

1980 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Barry D Nelkin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers

Kurzrock, R., Ball, D. W., Zahurak, M. L., Nelkin, B. D., Subbiah, V., Ahmed, S., O'Connor, A., Karunsena, E., Parkinson, R., Bishop, J. A., Ha, Y., Sharma, R., Gocke, C., Zinner, R., Rudek-Renaut, M., Sherman, S. I. & Azad, N., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5475-5484 10 p.

Research output: Contribution to journalArticle

  • O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis

    Taparra, K., Wang, H., Malek, R., Lafargue, A., Barbhuiya, M. A., Wang, X., Simons, B. W., Ballew, M., Nugent, K., Groves, J., Williams, R. D., Shiraishi, T., Verdone, J., Yildirir, G., Henry, R., Zhang, B., Wong, J., Wang, K-H., Nelkin, B. D., Pienta, K. & 3 others, Felsher, D., Zachara, N. E. & Tran, P. T., Nov 1 2018, In : The Journal of clinical investigation. 128, 11, p. 4924-4937 14 p.

    Research output: Contribution to journalArticle

  • Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

    Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L., Ali, H., Clary, D. O., Yaron, Y., Mangeshkar, M., Ball, D. W., Nelkin, B. D. & Sherman, S., Jan 1 2017, In : Annals of Oncology. 28, 11, p. 2813-2819 7 p.

    Research output: Contribution to journalArticle

  • Recent advances in the biology and therapy of medullary thyroid carcinoma

    Nelkin, B. D., Jan 1 2017, In : F1000Research. 6, 2184.

    Research output: Contribution to journalReview article

  • Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

    Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., Marayati, R., Kher, S., George, S. D., Xu, M., Wang-Gillam, A., Samatar, A. A., Maitra, A., Wennerberg, K., Petricoin, E. F., Yin, H. H. & 4 others, Nelkin, B. D., Cox, A. D., Yeh, J. J. & Der, C. J., Jan 11 2016, In : Cancer Cell. 29, 1, p. 75-89 15 p.

    Research output: Contribution to journalArticle